EUCTR2007-004824-19-AT进行中（未招募）不适用
Bevacizumab in Chronic Lymphocytic Leukemia: a proof of concept study - Avastin in C
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patient's written informed consent
- •B-CLL (as determined by CD23+, CD5+, CD19+, CD20+)
- •Treatment not yet indicated as defined by NCI Workshop Criteria, but with =1 risk factors (unfavourable molecular cytogenetics [17p and/or 11q and/or trisomy 12]; increased CD-38 level; increased ZAP70 expression; unmutated IgVH gene; or predicted lymphocyte doubling time shorter than 12 months)
- •Signs of advanced tumor mass or disease dynamics (fatigue or weight loss below NCI-definition, increase in bone marrow infiltration of more than 20% or absolute bone marrow infiltration rate of greater 70%, cytopenias due to splenomegaly below NCI criteria, lymph nodes above 3 cm or progressive lymphadenopathy below 50% in 6 month, leukocytosis greater than 100.000/µl)
- •ECOG performance status 0-2
- •No previous treatment of the CLL by chemotherapy, radiotherapy or immunotherapy
- •Life expectancy > 6 months
- •Patient using a reliable means of contraception (e.g. physical barrier, contraceptive pill or patch, spermicide and barrier, or IUD) for the duration of the treatment including 1 year thereafter
- •Adequate renal function as documented by:
- •- a serum creatinine level < 2 mg/dL (177 µmol/L)
- •- urine dipstick for proteinuria < 2+. If urine dipstick is = 2+, 24 hrs urine collection must demonstrate = 1 g protein secretion in 24 hours
- •Adequate hepatic function (total bilirubin = 1.5 x ULN, transaminases < 2.5 x ULN [or < 5 x ULN in the presence of CLL involvement of the liver])
- •The use of full dose oral or parenteral anticoagulants is permitted as long as the INR, or other monitoring test as appropriate, is within therapeutic limits and the patient has been on a stable dose of anticoagulants for at least 2 weeks at the time of enrolment. Patients not receiving anticoagulant medication must have an INR = 1.5 and an aPTT = 1.5 x ULN within 7 days of enrolment.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Uncontrolled viral, bacterial or fungal infection
- •History of solid organ transplantation
- •Pregnant or nursing females
- •CNS involvement by CLL or any evidence of spinal cord compression. Brain CT/MRI is only mandatory (within 4 weeks prior to enrolment) in case of clinical suspicion of CNS involvement by CLL.
- •CT scan based evidence of tumor invading major blood vessels (putting patients at risk for bleeding during study treatment)
- •Gastrointestinal tract involvement by CLL (test only upon clincal suspicion)
- •Prior malignancy (except adequately treated basal cell carcinoma of the skin, in situ cervical cancer, or any other cancer for which the patient has been in remission for at least 5 years)
- •Known hypersensitivity to study drug or its ingredients (i.e., hypersensitivity to Polysorbate 20, CHO cell products, or recombinant human antibodies)
- •Seizures requiring permanent anticonvulsant therapy
- •Severe chronic obstructive pulmonary disease with hypoxemia
- •Uncontrolled diabetes mellitus
- •Uncontrolled hypertension, CVA/stroke (= 6 months prior to enrolment), myocardial infarction (= 6 months prior to enrolment), unstable angina (= NYHA Grade IV), thrombosis within 6 months before enrolment, NYHA = Grade II CHF, or serious cardiac arrhythmia requiring ongoing medication
- •Clinically significant, active peripheral vascular disease, serious non healing wound/ulcer, bone fracture, bleeding diathesis (history or evidence of inherited bleeding diathesis) or coagulopathy
- •Major surgery, open biopsy or trauma within 28 days before enrolment (lymph node biopsies are not considered major surgery), or the need for major surgery during the course of study treatment
- •History of active ulcer (within 1 year prior to enrolment), abdominal fistula, gastrointestinal perforation, or intra abdominal abscess or concurrent therapy for treatment/prevention of ulcer
- •Current or recent (within the 30 days prior to starting study treatment) treatment with another investigational drug or participation in another investigational therapeutic study
- •Evidence of any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug, or patient at high risk from treatment complications
- •Any co-existing medical or psychological condition that would compromise ability to give informed consent
研究者
相似试验
Unknown
2 期
Combined Treatment With Fresh Frozen Plasma and Rituximab (Mabthera) in Patients With Advanced Refractory Chronic Lymphocytic LeukemiaAdvanced Refractory Chronic Lymphocytic LeukemiaNCT00892827Wolfson Medical Center10
招募中
3 期
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination with Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)Chronic Lymphocytic Leukemia2024-512147-23-00AbbVie Deutschland GmbH & Co. KG170
已完成
3 期
Rituximab Maintenance Versus Observation After First-line Immunochemotherapy by FCR in Older Patients With Chronic Lymphocytic LeukemiaLeukemiaNCT00645606University Hospital, Tours542
已完成
不适用
Phase IV Observational Study in Chronic Lymphocytic LeukemiaLeukaemia, Lymphocytic, ChronicNCT01453062GlaxoSmithKline1
进行中（未招募）
不适用
A Study to Assess Change in Functioning and Health Related Quality of Life in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Treatments in Routine Clinical Practice in SpainChronic Lymphocytic LeukemiaNCT06125795AbbVie146